The effect of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in gestational diabetes mellitus: a systematic review

References

• Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No.190: Gestational Diabetes Mellitus. Obstet Gynecol. 2018;131:e49–e64.
   PubMedGoogle Scholar
• Melchior H, Kurch-Bek D, Mund M. The prevalence of gestational diabetes. Dtsch Arztebl Int. 2017;114(24):412–418.
   PubMed Web of Science ®Google Scholar
• Li H, Song L, Shen L, et al. Height and risk of gestational diabetes mellitus: results from the Healthy Baby Cohort Study. J Diabetes Res. 2018;2018:4679245.
   PubMedGoogle Scholar
• Wu Y, Zhang J, Peng S, et al. Multiple elements related to metabolic markers in the context of gestational diabetes mellitus in meconium. Environ Int. 2018;121(Pt 2):1227–1234.
   PubMedGoogle Scholar
• Groof Z, Garashi G, Husain H, et al. Prevalence, risk factors, and fetomaternal outcomes of gestational diabetes mellitus in Kuwait: a cross-sectional study. J Diabetes Res. 2019;2019:1.
   Web of Science ®Google Scholar
• Venkataraman H, Ram U, Craik S, et al. Increased fetal adiposity prior to diagnosis of gestational diabetes in South Asians: more evidence for the 'thin-fat' baby. Diabetologia. 2017;60(3):399–405.
   PubMed Web of Science ®Google Scholar
• Brown J, Alwan NA, West J, et al. Lifestyle interventions for the treatment of women with gestational diabetes. Cochrane Database Syst Rev. 2017;5:CD011970.
   PubMed Web of Science ®Google Scholar
• Society of Maternal-Fetal Medicine Publications Committee. Electronic address, p.s.o., SMFM Statement: Pharmacological treatment of gestational diabetes. Am J Obstet Gynecol. 2018;218(5):B2–B4.
   Web of Science ®Google Scholar
• Rowan JA, Hague WM, Gao W, et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003–2015.
   PubMed Web of Science ®Google Scholar
• Barbour LA, Scifres C, Valent AM, et al. A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes. Am J Obstet Gynecol. 2018;219(4):367.e1–367.e7.
   Web of Science ®Google Scholar
• Ijas H, Vääräsmäki M, Saarela T, et al. A follow-up of a randomised study of metformin and insulin in gestational diabetes mellitus: growth and development of the children at the age of 18 months. BJOG. 2015;122(7):994–1000.
   PubMed Web of Science ®Google Scholar
• Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. BMJ Open Diab Res Care. 2018;6(1):e000456.
   PubMed Web of Science ®Google Scholar
• Balsells M, Garcia-Patterson A, Sola I, et al. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ. 2015;350:h102.
   PubMed Web of Science ®Google Scholar
• Kuna RS, Girada SB, Asalla S, et al. Glucagon-like peptide-1 receptor-mediated endosomal cAMP generation promotes glucose-stimulated insulin secretion in pancreatic beta-cells. Am J Physiol Endocrinol Metab. 2013;305(2):E161–70.
   PubMed Web of Science ®Google Scholar
• Ahren B, Sörhede Winzell M, Burkey B, et al. Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. Eur J Pharmacol. 2005;521(1–3):164–168.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Yanagimachi T, Fujita Y, Takeda Y, et al. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects. Mol Metab. 2017;6(2):226–231.
   PubMed Web of Science ®Google Scholar
• Stenlid R, Manell H, Halldin M, et al. High DPP-4 concentrations in adolescents are associated with low intact GLP-1. J Clin Endocrinol Metab. 2018;103(8):2958–2966.
   PubMed Web of Science ®Google Scholar
• Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016;12(10):566–592.
   PubMed Web of Science ®Google Scholar
• Foghsgaard S, Vedtofte L, Andreasen C, et al. Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect. Diabetologia. 2017;60(7):1344–1353.
   PubMed Web of Science ®Google Scholar
• Sukumar N, Bagias C, Goljan I, et al. Reduced GLP-1 secretion at 30 minutes after a 75-g oral glucose load is observed in gestational diabetes mellitus: a prospective cohort study. Diabetes. 2018;67(12):2650–2656.
   PubMed Web of Science ®Google Scholar
• Lencioni C, Resi V, Romero F, et al. Glucagon-like peptide-1 secretion in women with gestational diabetes mellitus during and after pregnancy. J Endocrinol Invest. 2011;34(9):e287–90.
   PubMed Web of Science ®Google Scholar
• Wibergl S, Hassagerl C, Schmidt H, et al. Exenatide for neuroprotection after out-of-hospital cardiac arrest, a double-blind randomized controlled trial. Circulation. 2016;134.
   Google Scholar
• le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet (London, England). 2017;389:1399–409.
   PubMed Web of Science ®Google Scholar
• Yan J, Yao B, Kuang H, et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology. 2019;69:2414–2426.
   PubMed Web of Science ®Google Scholar
• Santilli F, Simeone PG, Guagnano MT, et al. Effects of liraglutide on weight loss, fat distribution, and beta-cell function in obese subjects with prediabetes or early type 2 diabetes. Dia Care. 2017;40(11):1556–1564.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–341.
   PubMed Web of Science ®Google Scholar
• Sun X, Zhang Z, Ning H, et al. Sitagliptin down-regulates retinol-binding protein 4 and reduces insulin resistance in gestational diabetes mellitus: a randomized and double-blind trial. Metab Brain Dis. 2017;32(3):773–778.
   PubMed Web of Science ®Google Scholar
• Elkind-Hirsch KE, Paterson MS, Shaler D, et al. Short-term sitagliptin-metformin therapy is more effective than metformin or placebo in prior gestational diabetic women with impaired glucose regulation. Endocr Pract. 2018;24(4):361–368.
   PubMed Web of Science ®Google Scholar
• Foghsgaard S, Vedtofte L, Bahne E, et al. Treatment with the glucagon-like peptide-1 receptor agonist liraglutide improves glycemic control in women with prior gesta tional diabetes mellitus: a randomized, placebo-controlled trial. Diabetes. 2016;65:A490.
   Web of Science ®Google Scholar
• Hummel S, Beyerlein A, Pfirrmann M, et al. Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: a phase II, randomized, double-blind, placebo-controlled study. Mol Metab. 2018;9:168–175.
   PubMed Web of Science ®Google Scholar
• Foghsgaard S, Vedtofte L, Bahne E, et al. Intervention with a glucagon-like peptide-1 receptor agonist improves glycaemic control in women with prior gestational diabetes: a randomised, placebo-controlled trial. Diabetologia. 2016;59(1):S386.
   Google Scholar
• Kusunoki Y, Katsuno T, Nakae R, et al. Insulin resistance and beta-cell function influence postprandial blood glucose levels in Japanese patients with gestational diabetes mellitus. Gynecol Endocrinol. 2015;31(12):929–933.
   PubMed Web of Science ®Google Scholar
• Barbour LA, McCurdy CE, Hernandez TL, et al. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. Diabetes Care. 2007;30(Suppl 2):S112–S9.
   PubMed Web of Science ®Google Scholar
• Parlevliet ET, de Leeuw van Weenen JE, Romijn JA, et al. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 2010;299(2):E318–E324.
   PubMed Web of Science ®Google Scholar
• Chiswick C, Reynolds RM, Denison F, et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2015;3(10):778–786.
   PubMed Web of Science ®Google Scholar
• Dodd JM, Grivell RM, Deussen AR, et al. Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes. Cochrane Database Syst Rev. 2018;7:CD010564.
   PubMedGoogle Scholar
• Elmaraezy A, Abushouk AI, Emara A, et al. Effect of metformin on maternal and neonatal outcomes in pregnant obese non-diabetic women: a meta-analysis. Int J Reprod Biomed (Yazd). 2017;15(8):461–470.
   PubMed Web of Science ®Google Scholar